How to cite item

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study

   
@article{TCR24832,
	author = {Giandomenico Roviello and Daniele Generali and Navid Sobhani},
	title = {The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study},
	journal = {Translational Cancer Research},
	volume = {8},
	number = {Suppl 2},
	year = {2018},
	keywords = {},
	abstract = {The randomized phase III, double-blind, clinical trial (E5103) enrolled 4,995 patients with human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer and evaluated the efficacy and the safety of humanized monoclonal antibody bevacizumab targeting vascular endothelial growth factor (VEGF) in adjuvant chemotherapeutic setting (1).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/24832}
}